Stock Market Reviews

IMNM (Immunome, Inc.) News

Get the latest news, insights, and market updates on IMNM (Immunome, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73%
  Immunome, Inc. ( NASDAQ:IMNM ) shareholders will have a reason to smile today, with the analysts making substantial...
  Aug 9, 2025 - $IMNM
• Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates
  Immunome (IMNM) delivered earnings and revenue surprises of +3.85% and +62.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 6, 2025 - $IMNM
• Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?
  ABSCI CORP (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Aug 6, 2025 - $IMNM
• Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update
  BOTHELL, Wash., August 06, 2025--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2025 and provided a business update.
  Aug 6, 2025 - $IMNM
• Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates
  Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -18.75% and -55.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 6, 2025 - $IMNM
• OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee
  PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of exper
  Aug 6, 2025 - $IMNM
• Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates
  Jazz (JAZZ) delivered earnings and revenue surprises of -34.80% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 5, 2025 - $IMNM
• Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
  Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
  Jul 1, 2025 - $IMNM
• Immunome (IMNM) Upgraded to Buy: Here's What You Should Know
  Immunome (IMNM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  Jun 16, 2025 - $IMNM
• Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?
  The average of price targets set by Wall Street analysts indicates a potential upside of 158.2% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
  Jun 12, 2025 - $IMNM